LDS/Medical Tests/Interferon Lambda 3 (IFNL3) Gene Mutation Analysis

Interferon Lambda 3 (IFNL3) Gene Mutation Analysis

The IFNL3 (formerly IL28B) gene is located in the long (q) arm of chromosome 19 at position 13.2 and forms a cytokine gene cluster with other closely related cytokine genes, interleukin 28A (IL28A), and interleukin 29 (IL29). The gene encodes interferon lambda 3 protein which is expressed in response to microbial challenge and serves to activate the JAK/STAT signaling pathway. It plays a critical role in antiviral host defenses, and has antitumor and immunomodulatory activities. Polymorphisms in the gene have been identified as important factors in the ability of an individual to clear both Hepatitis C (HCV) and HTLV-1 viruses. Individuals with the favorable CC genotype have 50-55% viral clearance rates compared to 16-20% in patients with the CT or TT genotypes. Therefore, individuals with the CT and TT genotypes are more susceptible to developing chronic Hepatitis C and HTLV-1 associated myelopathy/tropical spastic paraparesis.

IFNL3 polymorphisms also impact the response to pegylated interferon/ribavirin used to treat HCV genotype 1 infections. Individuals with the CC genotype have a significantly higher response rate to PEG-interferon-alpha containing regimens than those with the CT or TT genotypes. However, a patient’s IFNL3 genotype is only one factor that could influence response rates to pegylated interferon/ribavirin combination therapy in HCV genotype 1 infection and should be interpreted in the context of other clinical and genetic factors.

  • To predict the treatment response with combined pegylated-interferon and ribavirin therapy in HCV genotype 1
  • To monitor the risk for hepatocellular carcinoma (HCC)
  • For the clinical management of Hepatitis C

Abnormal
IFNL3 genotype is CT or TT. This indicates that HCV genotype 1-infected individual has an unfavorable response genotype.

Normal
IFNL3 genotype is CC. This indicates that an HCV genotype 1-infected individual has favorable response genotype.

Presence of IFNL3 CC genotype, which is the good indicator of, sustained virologic response (SVR) for treating with combined pegylated-interferon and ribavirin therapy.

Next generation sequencing, Allele specific primer extension (ASPE or ARMS).

Whole Blood (EDTA), Saliva, buccal swab.

Stability

  • Ambient: 3-5 days
  • Refrigerated 7-14 days
HCV genotyping, HCV Ab test, Liver biopsy, liver function test, immunohistochemistry, H/E staining, HCV EIA test.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login